Newegg Commerce, Inc. annual report, FY2011

Filing identity and reporting period

Important source mismatch: The supplied filing is Dehaier Medical Systems Limited’s Form 10-K, not a Newegg Commerce, Inc. filing. It reports the fiscal year ended December 31, 2011, with 2010 as the comparable year; it is not a standalone fourth-quarter report.

Dehaier develops and distributes medical devices, with operations primarily in China. Its products include hospital equipment and respiratory and oxygen homecare products. It relies on third-party manufacturers and sells primarily through distributors.

Financial results and liquidity

Gross margin was 36.7%; operating income equaled approximately 16.7% of revenue and net income approximately 14.4%. The company used $3.16 million in operating cash despite reporting positive net income. Capital expenditures were approximately $0.15 million. Working capital was reported at $26.98 million, including cash of $3.69 million. Current assets were $31.63 million and current liabilities $4.65 million.

Year-end short-term borrowings were $1.59 million, due in 2012. The credit line was secured by a subsidiary’s building and guaranteed by a subsidiary and an officer. Total liabilities were $4.74 million; total equity was $30.23 million. Management said available working capital should support operations for at least 12 months.

Changes versus the prior year

• Revenue increased 10.4%, but net income attributable to Dehaier fell about 31.6% and diluted EPS declined from $1.09 to $0.69.
• Gross margin fell from 38.9% to 36.7%, which management attributed chiefly to higher product, assembly-part and labor costs, including inflation in China.
• Operating expenses rose about 67.9% to $4.50 million. General and administrative expense more than doubled to $2.62 million; selling expense rose 32.4% to $1.88 million.
• Respiratory and oxygen homecare revenue rose to $2.28 million, or 10.5% of revenue, from $0.44 million, or 2.25%. Medical-device revenue was $19.36 million, compared with $19.16 million.
• Net accounts receivable increased to $12.16 million from $9.11 million. The doubtful-account allowance rose to $859,509 from $87,555, following a change in the past-due threshold from three years to one year and reported collection delays.
• Operating cash use improved from $4.98 million to $3.16 million, but cash on hand still declined by $2.23 million during 2011.

Outlook, commentary and key risks

Management cited China’s healthcare investment, government procurement, an aging population and growing homecare demand as potential growth drivers. Its plans included expanding proprietary products, R&D, overseas distribution and home oxygen therapy services (HOTS). HOTS began in Beijing in 2011; management said 2012 would focus on building the delivery network rather than generating considerable revenue. No quantified company revenue or earnings guidance is provided.

• Receivables and cash conversion: Management reported distributor payment delays and expected longer collection periods and a higher risk of uncollectible receivables. Two customers each represented approximately 13% of 2011 revenue.
• Margin and expense pressure: Product and labor inflation reduced gross margin, while investment in projects, R&D, sales, international expansion and public-company costs increased expenses.
• Regulatory and product execution: Medical-device sales depend on SFDA approvals, certifications and renewals. Several CPAP and diagnostic products were still at the application stage; approval timing and market acceptance are uncertain.
• Supplier and distribution dependence: The company outsources production and depends on third parties for components and foreign-branded products. More than 90% of sales were through independent distributors.
• Customer and product concentration: Two customers each contributed about 13% of revenue. The three largest products represented 27% of revenue, down from 53% in 2010.
• Other items: A $221,640 favorable change in warrant fair value supported 2011 earnings; 2010 included approximately $443,000 of local-government income for the U.S. listing, versus approximately $27,423 of subsidy income in 2011. The company also disclosed unresolved tax issues and unfiled 2008 and 2009 VAT returns for some customers, with potential VAT liabilities accrued.
• The company stated that it was not required to provide a formal Item 1A risk-factor disclosure because it was a smaller reporting company. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor expressed no opinion on internal-control effectiveness.

Most important facts to verify

1. Confirm the issuer and period: the supplied document is Dehaier’s FY 2011 10-K, not a Newegg filing or a quarterly report.
2. Review the aging, subsequent collections and reserve adequacy for the $12.16 million of net receivables and the increased doubtful-account allowance.
3. Assess why operating cash flow remained negative despite reported earnings, and whether working capital is available to fund operations and growth.
4. Check the status and renewal of SFDA registrations, pending product approvals, and the commercial progress and economics of HOTS.
5. Confirm repayment and refinancing of the $1.59 million short-term borrowing, including the disclosed 2012 due dates and collateral arrangements.
6. Evaluate customer concentration, third-party supplier exposure, and the sustainability of margins amid cost inflation and higher operating expenses.